Medical Condition

nasopharyngeal carcinoma

Total Trials

14

Recruiting Now

14

Trial Phases

Phase 1, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for nasopharyngeal carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — nasopharyngeal carcinoma Clinical Trials

How many clinical trials are currently recruiting for nasopharyngeal carcinoma?

ClinicalMetric currently tracks 14 actively recruiting clinical trials for nasopharyngeal carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for nasopharyngeal carcinoma?

nasopharyngeal carcinoma research spans Phase 1 (1 trial), Phase 2 (4 trials), Phase 3 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a nasopharyngeal carcinoma clinical trial?

Eligibility criteria for nasopharyngeal carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Sun Yat-sen University 5 trials

National Cancer Institute (NCI) 1 trial

Taizhou Hospital 1 trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 1 trial

Wei Jiang 1 trial

Recruiting Clinical Trials

NCT06479811 Phase 1

Recruiting

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

National Cancer Institute (NCI...

View Trial →

NCT05342792 Phase 3

Recruiting

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Sun Yat-sen University

View Trial →

NCT04813705 Phase 2

Recruiting

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Sun Yat-sen University

View Trial →

NCT06463392

Recruiting

Deep Learning-based sbORN Diagnostic Model

Sun Yat-Sen Memorial Hospital ...

View Trial →

NCT05527470 Phase 3

Recruiting

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Sun Yat-sen University

View Trial →

NCT05340491 Phase 3

Recruiting

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Sun Yat-sen University

View Trial →

NCT05147844 Phase 2

Recruiting

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Xinqiao Hospital of Chongqing

View Trial →

NCT05126160

Recruiting

Immune Score Based Radiomics in Nasopharyngeal Carcinoma

Zhejiang Cancer Hospital

View Trial →

NCT06059261 Phase 2

Recruiting

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Chongqing University Cancer Ho...

View Trial →

NCT06529562

Recruiting

Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

German Society for Pediatric O...

View Trial →

NCT04136886 Phase 3

Recruiting

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

Sun Yat-sen University

View Trial →

Related Conditions

sinonasal neuroendocrine carcinoma (1) esthesioneuroblastoma (1) olfactory neuroblastoma (1) somatostatin receptor positive (1) small cell lung cancers (1) pheochromocytoma paragangliomas (1) kidney cancers (1) head and neck tumors (1) gastrointestinal neuroendocrine tumors (1) multi omics technique (1) recurrent and metastatic nasopharyngeal carcinoma (1) efficacy of chemoradiotherapy and immunotherapy (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology